System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Gilles Montalescot is an expert in Cardiology at Pitié-Salpêtrière Hospital (France). As of October 2026, ScienceLeadR ranks Gilles Montalescot in the top 1% of experts worldwide for Myocardial Ischemia, Angina Pectoris and Coronary Disease. Gilles Montalescot has authored 1,116 publications, the most recent in 2026, and is an investigator in 98 clinical trials, 8 of them ongoing. SLR score: 5,105 (community average: 125). How the SLR is computed.

LeadR Profile

Gilles Montalescot Pitié-Salpêtrière Hospital France
5 105 ScienceLeadR Reputation 5105

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Biostatistics - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1988 - 2026
Source: PubMed

Pitié-Salpêtrière Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1116

Citations

Citations: 107 346 1st author: 103 Last author: 270 Unique author: 25

Main journals

Eur Heart J 160
J Am Coll Cardiol 113
Circulation 74
Am Heart J 64
JACC Cardiovasc Interv 45

Best Journals

Eur Heart J 46
N Engl J Med 44
JAMA 15

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prevalence, Predictors, and Clinical Implications of Residual Shunt After Patent Foramen Ovale Percutaneous Closure.
PMID 42862913 — foramen ovale, patent, prevalence, blood circulation, foramen ovale		Circulation Top journal20260
Response to letter by Güner et al. regarding "Predictive score for supraventricular arrhythmia after patent foramen ovale percutaneous closure".
PMID 42829282 — foramen ovale, patent, arrhythmias, cardiac, cardiovascular diseases, foramen ovale		Arch Cardiovasc Dis20260
Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
PMID 42669300 — myocardial infarction, heart failure, heart, therapeutics		Lancet Top journal20262
Prognostic impact of pericardial effusion in patients with acute myocarditis.
PMID 42670209 — pericardial effusion, cardiovascular diseases, phenotype, myocarditis, echocardiography		Eur Heart J Acute Cardiovasc Care20261
Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.
PMID 42670293 — diabetes mellitus, mortality, ischemic stroke, stroke, myocardial infarction, lipoproteins, cardiovascular system, lipoproteins, hdl, cholesterol, atherosclerosis, lipoproteins, ldl, blood circulation, ischemia, apolipoproteins		Circulation Top journal20262

Clinical Studies 98

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 11 Study Chair: 2 Study Director: 2

By phase:

Phase 3 48
N/A 25
Phase 4 13
Phase 2 8
Phase 2/Phase 3 3
Phase 1 1

By status:

Completed 73
Terminated 10
Active not recruiting 6
Recruiting 5
Unknown 3
Withdrawn 1

By type:

Interventional 87
Observational 11

By Monocentric/Multicentric:

monocentric 42
multicentric2to4 11
multicentric5to9 2
multicentricup10 43

Main Topics

Cohort/Consortium Investigators 9

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Evaluating the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
2023-507407-59-00 — multiple chronic conditions, pulmonary disease, chronic obstructive, fumarates, metered dose inhalers, formoterol fumarate, therapeutics, lung diseases, lung diseases, obstructive, budesonide		Phase 3Recruiting2024
A Phase 3 Randomized Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of MK 0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
2022-502781-24-01 — heart diseases, safety, heart, cardiovascular diseases, coronary disease		Phase 3Active not recruiting2024
Evaluation of the Vivo Isar Stent System in Routine Clinical Practice
NCT06420505 — myocardial ischemia, stents, constriction, pathologic, heart diseases, polymers, heart, percutaneous coronary intervention, sirolimus, coronary stenosis, arteries		N/ARecruiting2023
Impact of YOGA on the Quality of Life and Well being of Heart Failure Patients
NCT06019169 — quality of life, pilots, yoga, heart failure, heart, contraindications, therapeutics		N/ARecruiting2024
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
NCT05213104 — foramen ovale, patent, ischemic stroke, stroke, arrhythmias, cardiac, acetates, atrial fibrillation, tachycardia, flecainide, foramen ovale		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS